The Fiber Disease

Human Anatomy, Physiology, and Medicine. Anything human!

Moderator: BioTeam

Posts: 40
Joined: Mon Nov 28, 2005 5:24 am

Post by FiberSymptoms » Fri Nov 24, 2006 3:42 pm

Last edited by FiberSymptoms on Sat Dec 02, 2006 10:18 pm, edited 1 time in total.

User avatar
Posts: 129
Joined: Wed Aug 30, 2006 4:37 am

Post by mfromcanada » Fri Nov 24, 2006 3:44 pm

msc, perhaps our posts are not being answered because they have been removed or altered. Thanks for the update on retinoids. Does this mean that the vitamin A cream that my derm manufactures and sells to his patients is actually agrivating this condition. I am outraged as he actually yelled at me a couple of weeks ago in his office: "Stop picking at your skin". He then tells me I have exzema and dry skin. "What do you use to clean your face? Have you ever put a moisturizer on your skin/ etc. " I was disgusted. DR.TELFORD. I can't believe how badly we are treated.

Posts: 406
Joined: Wed Oct 26, 2005 12:56 pm

Post by tamtam » Fri Nov 24, 2006 3:52 pm

Why not classify a GMO?

R. Seeberi maybe indeed, but not the old one!

Classification will cause debate.
Last edited by tamtam on Fri Nov 24, 2006 4:06 pm, edited 2 times in total.

User avatar
Posts: 268
Joined: Sun Aug 07, 2005 8:03 pm

may the buyer beware

Post by Sabrina » Fri Nov 24, 2006 4:43 pm

Got this e-mail today, thought I would pass it on.

Morgellons Research Foundation
A nonprofit organization

Dear Sabrina,

We sincerely apologize for the gap in emails from the MRF. We have been unable to send emails to our registrants since last spring. We have regained our emailing capability and will now be updating you on a regular basis. We have several things to tell you:

1. Research:

Dr. Wymore is continuing his research efforts at OSU to understand Morgellons disease. We have given Dr. Wymore funds to help his research efforts, and we have also given funds to a researcher at another major university. We have recently been contacted by three more research groups, who have expressed an interest in researching Morgellons disease. We will update you as we learn anything new from any of these researchers.

2. CDC:

The CDC (Centers for Disease Control and Prevention), is currently
investigating Morgellons disease. CDC has formed a 12 person Morgellons task force devoted to this investigation.

You can call the pre-recorded Morgellons disease info line at CDC to hear a brief statement about this illness. Morgellons information and voicemail line: 404-718-1199

You can email the CDC about Morgellons here:
[email protected]

The CDC, in conjunction the CA Department of Health Services, will soon be launching an official investigation in the state of California. We will update you on this situation, as we learn more.

3. States:

Several people have offered to help organize the individuals in their states
with Morgellons disease. We are in need of people in most states to help with this extremely important effort. Although we do hope to establish support groups for people with Morgellons disease, the specific purpose of this particular effort is not for support, but for political action. We realize the importance of individuals within states to organize their efforts, but also realize that this illness prevents many people from being able to do this type of demanding work. If you feel that you would be able to help in this state organizing effort, please email a letter about your interest, including your name, address, phone number, and email address here:

Please be sure to put the name of your state in the subject field.
[email protected]

4. Children:

If you have children with Morgellons disease, and would like to join an effort to help all children with this disease, please email us at the address below. If you would be willing to work hard to help organize the parents in this group, please put "Organize parents" in the subject line. Please also include the your name, address, phone number, email address, as well as the names, ages and symptoms of affected children. Even if you are unable to help organize this effort, we do want to be aware of all
children with this illness. Please contact us here:
[email protected]

5. Politicians:

If you have a copy of a letter, which was sent by a politician to any government agency ( CDC, NIH, or state health dept ) on your behalf, this is very important and we would like to see a copy of this letter . If the politician received a letter from a government agency in response to their inquiry, please scan and email both of these important letters here:
[email protected]

6. Nurses:

The MRF Board of Nursing is a very dedicated group of 5 RNs who are working on your behalf to help establish the validity of Morgellons disease. We will update you on the efforts of these nurses in the next few weeks.

7. National Hot Rod Association (NHRA)

David Baca, who is a driver for the NHRA, will be driving with the words
"Morgellons Research Foundation" on his car during this weekend's (Nov 11-14) 42nd annual Auto Club of Southern California NHRA Finals in Pomona, California. Please watch for this event on ESPN2.

NHRA Press Release:

Click here: Automobile Club of Southern California NHRA Finals: Mach 1 Air Services dragster
Race schedule (dates, times, drivers):
Click here: MRF - Media Alert

William T. Harvey, MD, MPH, who has been working with us since 2003, became theMRF Board Chairman in July. Dr. Harvey is continuing his unyielding efforts to help our group gain acceptance within the medical community, and wishes to give the following message to all people with Morgellons disease:

" We, at The MRF, are working on behalf of each and every one of you, to fully understand the cause of, and treatment for, Morgellons disease. We are working to fully characterize this illness, in terms of patient history, signs and symptoms, as well as laboratory abnormalities and optimal treatment. Rest assured that we will find answers to all of the questions posed by this illness, and that we believe the time to do this is now.
~William T. Harvey, MD, MPH

Please know that we are working as quickly as possible, and that we care!

Mary M. Leitao
Executive Director
Morgellons Research Foundation


King Cobra
King Cobra
Posts: 1277
Joined: Thu Nov 17, 2005 3:41 am

Post by London » Fri Nov 24, 2006 6:24 pm


No offense to you and thank you for sharing your mail but that person should be in jail......for laundering money??? hehehe , hell, I don't think she did, but even if she did, why that is nothing compared to the friggin Hell she has caused us. She makes me think of E.coli.......

I'd like to clone a rat, rabbit, chicken and guinne pig and let them hatch in her stomache.....the rotting black fungus of a lining stomach.

Thanks Mary for being in cahoots w/ JJ and Ken and covering up / maybe participating in burning innocent individuals with radiation toxicities. You and JJ can go on back to Asia and go shopping......but not like a normal young lady know for shoes.....But go like you really are : A MONSTER that kisses Arse and go shopping for you gals some plasma beams, transitors.......go have a nother drink with sleazeball expertise. or how about go shopping for some more arsinic, or poisionous plants to clone our arses with. How dare you participate in this atrocious disease that you cover. Prove me wrong, show your proof, meet with me. Show me your family is sick. IF YOU CAN PROVE ME WRONG, I will find someway to get you First Class vacation to the destination of your choice.

I hope to God I never see your face.

I'm sorry you guys, offense to any of you but I have a right to speak my mind, don't I? If this offends anyone of you I will erase it.


Chapter 14: The Federal Policy for Human Subject Protections (The Common Rule)
The Common Rule applies to all federally funded research conducted both intra- and extramurally. The rule directs a research institution to assure the federal government that it will provide and enforce protections for human subjects of research conducted under its auspices. These institutional assurances constitute the basic framework within which federal protections are effected. Local research institutions remain largely responsible for carrying out the specific directives of the Common Rule. They must assess research proposals in terms of their risks to subjects and their potential benefits, and they must see that the Common Rule's requirements for selecting subjects and obtaining informed consent are met.

As discussed below, central to the process of ensuring that the rights and well-being of human subjects are protected are institutional review boards (IRBs). The Common Rule requires that a research institution, as a condition for receiving federal research support, establish and delegate to an IRB the authority to review, stipulate changes in, approve or disapprove, and oversee human subjects protections for all research conducted at the institution. IRBs are generally composed of some combination of physicians, scientists, administrators, and community representatives, usually at the local research institution, but sometimes at an agency that conducts intramural research.[7] IRBs have the authority to suspend the conduct of any research found to entail unexpected or undue risk to subjects or research that does not conform to the Common Rule or the institution's additional protections.

A prominent feature of the Common Rule is the informed consent requirement. The informed consent of a competent subject, along with adequate safeguards to protect the interests of a subject who is unable to give consent, is a cornerstone of modern research ethics, reflecting respect for the subject's autonomy and for his or her capacity for choice. Informed consent is an ongoing process of communication between researchers and the subjects of their research. It is not simply a signed consent form and does not end at the moment a prospective subject agrees to participate in a research project.

The required elements of informed consent stipulated by the Common Rule are summarized as follows:

A statement that the study involves research, an explanation of the purposes of the research, and a description of the procedures to be followed;
A description of any reasonably foreseeable risks or discomforts to the subject;
A description of any benefits to the subjects or to others that might reasonably be expected;
A disclosure of alternative procedures or courses of treatment;
A statement describing the extent to which confidentiality of records identifying the subject will be maintained;
For research involving more than minimal risk, an explanation of the availability and nature of any compensation or medical treatment if injury occurs;
Identification of whom to contact for further information about the research and about subjects' rights, and whom to contact in the event of a research-related injury; and
A statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and that the subject may discontinue participation at any time.[8]
The Common Rule includes several additional elements of consent that may be appropriate under particular circumstances[9] and describes the conditions under which an IRB may modify or waive the informed consent requirement in particular research projects.[10]

When an IRB reviews and approves a research project, it must pay particular attention to the project's plan for obtaining subjects' informed consent and to the documentation of informed consent. The IRB may require changes in the investigator's procedure for obtaining informed consent and in the consent documents. The board also must be allowed to observe the informed consent process if the IRB considers such oversight important in ascertaining that subjects are being adequately protected by that process.[11]



Tam Tam, Great Hyperlink up above......Loved the first one especially....

Lasers......Thank You Lil TamTam.......

King Cobra
King Cobra
Posts: 1277
Joined: Thu Nov 17, 2005 3:41 am

Post by London » Fri Nov 24, 2006 6:48 pm

Uh Oh..................Hey Tam Tam.......dunno if you wanted us to find this, I think you did.,....for it was the second time you posted this sentence....

Filament production by Strain 001.......Well, I got this......Man o' Man.....I have not even read all of it .....just wanted to share w/ you guys.....

and Tam, the last time you posted the above sentence you had cyanobacteria in the sentence before it.....

Is this what you wanted us to find?

Thanks Tam Tam

Here is just a snippet of it:

2. The method of claim 1 in which the target gene is a cellular gene.

3. The method of claim 1 in which the target gene is an endogenous gene.

4. The method of claim 1 in which the target gene is a transgene.

5. The method of claim 1 in which the target gene is a viral gene.

6. The method of claim 1 in which the cell is from an animal.

7. The method of claim 1 in which the cell is from a plant.

8. The method of claim 6 in which the cell is from an invertebrate animal.

9. The method of claim 8 in which the cell is from a nematode.

Death Adder
Death Adder
Posts: 91
Joined: Sun Nov 19, 2006 6:09 am

Post by msc » Sat Nov 25, 2006 3:45 am


i am having a difficult time with this entire blog session and mrf and osu.
osu has had samples sent from my friend since august. they had copies
of three patents and dangerous harmful chemicals not listed on the patients insersert and label of this fda prescription cream. they have copies of an eight page full description patent view, that states isotopes,
hydrophilics and lipophilics, lecithins, coloids, flourescent iron and metal oxides, flourescent coloured pigments, accutane, isotretinoin, trettinoin,
ttnpb, cis-13 retinoids, cis-9 rietinoids, atar retinoids and a host of
toxic chemicals in the use of making polyethyelene, electro static, and
photons, corrosives and formaldyhe and pesticides, silicone and silica
nano particles. they have dr. staninger's pathologist report listing
silicone, silica and high dense polyethyelen and fiber optics found in two women tested, who never worked in an industry that develops these products. would it not be intelligent to take a patient who has detailed
documents, photos, medical records and patents that on a product she used and tests her samples of hair and clothing sent that show this clear
translucent object with srong black fibers like hair and crystals attached to it. would not that alleveiate and alot of needless costs and lead to an
agency and organization that caused this infectious disease? where is common sense. why does that person keeping leaving blogs on mitchodria. what are they trying to say and why don't they just come out and say what they want to say instead of sending people who are sick and tired and can barely see on a hunting expedition? a simple lab test
of hair, sputum, eye and nose culture would tell what they did, as well as
blood and urine tests, no body needs to be cut and dissected anymore.
let's alleviate alot of stress and pain and get to the bottom of it now.
let these people have peace of mind for the christmas holiday. the fact that drugs were being deliberately mislabeled and misadultered is a severe enough crime to have people punished. the face that physicians
did no tests at all on patients is a crime in itself and they need to be disbarred from practicing medicine and put in a jail cell for defamation
of characters of their patients, putting their patient's lives in danger and
their families, for insurance fraud. it is time that the so called professionals who broke the laws pay like the rest of us who would break the law and hurt someone. no one is above the law. under 42 uscs 1983
civil rights law, any gov't official having knowledge of a crime and does
nothing and prevents witnesses from testifying are to be held accountable.
committing false reports is perjury and is subject to 5 years in jail and
$10,000.00 fine or both. a medical phyisican, psychiatrist and forensic
pyschologist have submitted false reports on a person who was forced to
suffer for seven long years. can't all of you right to the cdc, who has documents on this patient under PRIUSA R w Johnson, the FBI 5/10/2004
FILE CE 209-0 special agent Chris Swecker who though it wasn't the fbi's
responsibilty advised her to go to state agencies, which he had already
seen per doc. she sent him that she had already done that. under fbi's 9/11 bio terrorism alerts, shouldn't that have been a major concern to the fbi? or did they know what this corp. developed in a biological and radioactive cream. the fbi mailed back all her samples, they sent through
the mail radioactive and biological contaminated samples as, did dyfs
and the nj medical examiner william roeder, who first mailed her samples
to the wrong patient who had also field a complaint. at that time my friend did't know they used chemo therapy and biological hazardous agents, she didn't know until two months ago. you want something done
now stand up and do something constructive. put your money where your mouth is and demand answers and end the game they played and are still playing.

Nadas Moksha
Posts: 248
Joined: Thu Aug 10, 2006 7:41 am

Post by Nadas Moksha » Sat Nov 25, 2006 4:18 am

new and putz to sleep ...ropinirole????Update on mycoterrorism
D.W. Warnock Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta,Georgia, USA
In the fall of 2001, envelopes containing Bacillus anthracis spores were mailed to news media companies and government officials in the United States, leading to 11 inhalational and 11 cutaneous cases of anthrax; 5 of the inhalational cases were fatal. 20 case-patients were either mail-handlers or were exposed to worksites where contaminated mail was processed or received. Illness and death occurred not only at targeted worksites, but also along the path of mail and in other settings. During this first bioterrorism (BT)-related outbreak, laboratories tested more than 125,000 clinical specimens, and around 1 million environmental specimens. Around 10,000 persons were offered post-exposure antimicrobial prophylaxis to prevent inhalational anthrax.
Against this background, might the deliberate release of a fungal agent pose a credible threat to public health? The first question that needs to be considered is what agent might be used. Coccidioides immitis is a potential candidate. It has a restricted geographic distribution and can cause serious or lethal disease in previously unexposed normal persons. As with anthrax, natural infection with C. immitis occurs after inhalation of aerosolized spores from an environmental source. However, several features might make C. immitis less attractive to a potential terrorist. In marked contrast to inhalational anthrax, fewer than 50% of exposed individuals develop symptomatic infection, usually 1-3 weeks after exposure. Furthermore, less than 1% of cases progress to serious and lifethreatening local or disseminated infection following natural exposure. In most instances, this occurs within 12 months of the initial infection, although it can develop much later following reactivation in an immunosuppressed individual. Again, in marked contrast to inhalational anthrax, most cases of C. immitis infection resolve without antimicrobial treatment, usually within 2-3 weeks. Consideration of the potential for intentional use of this fungal agent highlights several deficiencies in our current ability to detect and respond to C. immitis infections. The deliberate release of C. immitis among the population of a nonendemic region would be difficult to detect because there is no surveillance system for coccidioidomycosis outside the endemic states of the southwestern USA. Confirmation of a clinical diagnosis of acute pulmonary coccidioidomycosis still depends on serologic tests for antibodies that, at the earliest, do not appear until 1-3 weeks after the onset of symptoms. More research is also needed to develop methods for the rapid detection of C. immitis in powders or other potential vehicles, and to evaluate procedures for the remediation of health risks in environments contaminated as a result of the deliberate release of C. immitis. Finally, it is unclear whether existing drugs would provide safe and effective postexposure prophylaxis for prevention of illness among exposed persons. At this time, C. immitis is not included on the CDC list of potential BT agents that require special action for public health preparedness. Nevertheless, it is classed as a select agent and its possession, use and transfer is subject to stringent regulation. The Category A list of potential bacterial and viral BT agents includes 6 organisms and diseases of greatest concern (including anthrax, botulism, plague and smallpox) that can be easily disseminated, or once disseminated can be transmitted from person to person, that cause high mortality, that have the potential for major public health impact, and that have the clear potential to cause public panic and social disruption. Other agents are included as Category B or C because they are moderately easy to disseminate, even though they only cause moderate morbidity and low mortality. There are those who argue that the use of C. immitis in a non-endemic region should be considered for inclusion in Category B or C.


Nadas Moksha
Posts: 248
Joined: Thu Aug 10, 2006 7:41 am

Post by Nadas Moksha » Sat Nov 25, 2006 4:34 am

ohh and about msc retina and its use...
you dont have to be a user to have it contaminate your enviroment

and tams been correct too many times especially on the azole... .

Fabrication of microchambers defined by photopolymerized hydrogels and weirs within microfluidic systems: application to DNA hybridization; Seong GH et al.; This paper describes fabrication of serial microchamber arrays within the channels of a microfluidic device . The chambers are defined using a combination of weirs and UV-cross-linked hydrogel plugs (poly(ethylene glycol) diacrylates) . This approach permits the microchambers to be addressed by pump-driven pressure in one dimension and by electrophoresis in the other . The function of the device is demonstrated by detecting DNA targets . Single-strand DNA (ssDNA) probes labeled with biotin were immobilized onto microbeads coated with streptavidin . The DNA-functionalized microbeads were packed into each of three microchambers by injection through inlet wells . Three oligonucleotides were designed as probes and four as targets . Hybridization reactions were performed by moving the targets across the array of probe-containing microchambers by electrophoresis . The hybridization of fluorescein-labeled ssDNA targets to complementary probes was observed by fluorescence microscopy . These studies resulted in four key observations: (1) there was no detectable binding of targets to noncomplementary probes; (2) hybridization was 90% complete within 1 min; (3) once captured, the targets could be independently released and recovered from the microbeads by treatment with 0.1 N NaOH; (4) multiple analyses could be performed using a single bead set, but there was degradation in performance after each capture/release cycle.

Cell Motil Cytoskeleton, 2002 Jun, 52(2), 97 - 106
Micropatterning tractional forces in living cells; Wang N et al.; Here we describe a method for quantifying traction in cells that are physically constrained within micron-sized adhesive islands of defined shape and size on the surface of flexible polyacrylamide gels that contain fluorescent microbeads (0.2-microm diameter) . Smooth muscle cells were plated onto square (50 x 50 microm) or circular (25- or 50-microm diameter) adhesive islands that were created on the surface of the gels by applying a collagen coating through microengineered holes in an elastomeric membrane that was later removed . Adherent cells spread to take on the size and shape of the islands and cell tractions were quantitated by mapping displacement fields of the fluorescent microbeads within the gel . Cells on round islands did not exhibit any preferential direction of force application, but they exerted their strongest traction at sites where they formed protrusions . When cells were confined to squares, traction was highest in the corners both in the absence and presence of the contractile agonist, histamine, and cell protrusions were also observed in these regions . Quantitation of the mean traction exerted by cells cultured on the different islands revealed that cell tension increased as cell spreading was promoted . These results provide a mechanical basis for past studies that demonstrated a similar correlation between spreading and growth within various anchorage-dependent cells . This new approach for analyzing the spatial distribution of mechanical forces beneath individual cells that are experimentally constrained to defined sizes and shapes may provide additional insight into the biophysical basis of cell regulation .

hey brave souls check out this map

King Cobra
King Cobra
Posts: 1277
Joined: Thu Nov 17, 2005 3:41 am

Post by London » Sat Nov 25, 2006 6:01 am

OKAY, I'm back here again apologizing. I am reforming my bad habits and faults and emptying out my garbage can.(Sorry Mary L).... Then, in this Dharma-ending Age, the world can borrow your light and hold out a little longer (no pun intended)

Karma......I just never did anything to deserve this......anyway, sorry to be offensive. I have just been a wreck b/t extremely sad, to irrate.

I just do not understand the hatred and the evil. Why. What's the purpose? This is satanic isn't it?

Please share with us why we were chosen.

Okay, TamTam, will you tell us why? I mean apparently the computer graphic artist either hates us or is being paid handsomely by some gov't authority.

Also, Tam, Are you wanting us to find this an post it? Then where will you go? why has n't anyone untited?

I will be game to unite......Any others?

Again, My apologies to Ms. Leiato and you guys too.

Nadas Moksha
Posts: 248
Joined: Thu Aug 10, 2006 7:41 am

Post by Nadas Moksha » Sat Nov 25, 2006 6:39 am

The situation changed in 1949 when the CDC brought on board Alexander Langmuir, an associate professor at the Johns Hopkins University School of Hygiene and Public Health. Langmuir was the CDC's first VIP, bringing with him both his expertise in epidemiology (the statistical study of epidemics) and his high-level connections -- including his security clearance as one of the few scientists privy to the Defense Department's biological warfare program...
...Langmuir and talked public officials and Congress into giving the CDC contingent powers to deal with potential emergencies... In July of 1951 he assembled the first class of the Epidemic Intelligence Service (EIS), composed of twenty-three young medical or public health graduates. After six weeks of intensive epidemiological training, these EIS officers were assigned for two years to hospitals or state and local health departments around the country. Upon completing their field experience, EIS alumni were free to pursue any career they desired, on the assumption that their loyalties would remain with the CDC and that they would permanently act as its eyes and ears. The focus of this elite unit was on activism rather than research and was expressed in its symbol -- a shoe sole worn through with a hole. According to British epidemiologist Gordon Stewart, a former CDC consultant, the EIS was nicknamed the "medical CIA “----Duesberg's Inventing The AIDS Virus (1996) (Source:
"The Centers for Disease Control has had three major programs through which it can make diseases appear infectious and make everyone step in line to agree. One is that in the early 1950s they formed a special unit, an elite, semi-secret unit, that is now almost fully secret, called the Epidemic Intelligence Service, or EIS. New graduates of medical schools, or biological graduate schools, or perhaps dental schools, or a few other things, public health departments, are recruited upon graduation to take a several-week course, and then dispatched on two-year active assignment, paid by the CDC, in various local and state health departments to become the eyes and ears of the CDC—an invisible intelligence network that watches for the tiniest clusters of disease, and, when the CDC deems appropriate, turns them into national emergencies. We saw this kind of cynical manipulation in the 1957 Asian flu epidemic. We saw it in the 1960s with clusters of leukemia, which they tried to make appear infectious. We saw that with the swine flu epidemic that never materialized, in 1976, and with the Legionnaire's epidemic that same year. And we've seen it more recently with Lyme disease, with Hantavirus pneumonia, and just one thing after another."

Disease theory

“[T]here’s fame, fortune, and big budgets in sounding the ‘emerging infection’ alarm and warning of our terrible folly in being unprepared.”-------Michael Fumento, National Post, March 28, 2003


Nadas Moksha
Posts: 248
Joined: Thu Aug 10, 2006 7:41 am

Post by Nadas Moksha » Sat Nov 25, 2006 7:06 am

Department of Biomedical Engineering & Bioengineering Center
The exceptional solubility in vivo (20-30% w/v) of the silk proteins of insects and spiders is dictated by boththe need to produce solid fibres with a high packing fraction and the high mesogen concentration required for lyotropic liquid crystalline spinning. A further design requirement for silk proteins is a strong predominance of hydrophobic amino acid residues to provide for the hydrophobic interactions, water exclusion, and betacrystallite formation required to produce strong insoluble threads. Thus the domain structure of silk proteins needs to enable nanoscale phase separation to achieve high solubility of hydrophobic proteins in aqueous solutions. Additionally silk proteins need to avoid premature precipitation as β-sheets during storage and processing. Here we use mapping of domain types, sizes and distributions to identify consistent design features that have evolved to meet these requirements. We show that silk proteins consist of conspicuously hydrophilic domains flanking a very long central portion constructed from hydrophobic blocks separated by hydrophilic ones, discussing the domain structure in detail. The general rules of construction for silk proteins based on our observations should give a useful guide to the way in which Nature has solved the problem of processing hydrophobic proteins in water and how this can be copied industrially. Following these rules may also help in obtaining adequate expression, soluble products and controllable conformational switches in the production of genetically engineered or chemically synthesized silk analogues.

Biopolymer Engineering - Structure-Function Relationships and Supramolecular Assembly - The interface between biology and biopolymer science and engineering is a focus of our research program. Our efforts areaimed at understanding biological synthesis and processing of polymers within the context of polymer/materials science. This understanding is relevant to molecular recognition, self-assembly and the formation of materials with well-defined architectures, as well as biomaterials and tissue engineering utility. We utilize a variety of experimental strategies to gain insight into these areas: (1) genetic engineering exploration of the molecular genetics of biosynthesis pathways for biopolymers, (2) whole cell physiology - manipulation of the cell environment to regulate the chemical and physical features of the biopolymer synthesized, and (3) enzymatic - polymer synthesis or modification using enzymes in vitro in novel environments. In all cases, our aim is to manipulate the structure of biopolymers as a route to understand and control assembly, molecular recognition and biological interactions. In addition, since the synthesis, modifications and processing of these polymers are carried out within a biological context, issues related to green chemistry and environmentally-compatible processes are fostered.
Biomaterials & Tissue Engineering – The impact of selective environmental factors (e.g., growth factors,mechanical stress) on stem cell differentiation, the relationship between biomaterial structure
(supramolecular assembly) and stem cell responses, and the role for complex bioreactor designs to study these interactions are current areas of inquiry. We are particularly interested in how environmental cues
(biomaterial structure/architecture, mechanical forces) influence stem cell processes and tissue engineering outcomes using both in vitro and in vivo studies. ... earch2.pdf.


Who is online

Users browsing this forum: Google [Bot] and 0 guests